5-(3,5-difluorobenzenesulfonyl)-3-(trifluoroacetamido)-1-tritylindazole | 1034975-81-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 5-(3,5-difluorobenzenesulfonyl)-3-(trifluoroacetamido)-1-tritylindazole
• 英文别名: N-[5-(3,5-difluoro-benzenesulfonyl)-1-trityl-1H-indazol-3-yl]-2,2,2-trifluoro-acetamide；N-[5-(3,5-difluorophenyl)sulfonyl-1-tritylindazol-3-yl]-2,2,2-trifluoroacetamide
• CAS: 1034975-81-9
• 化学式: C₃₄H₂₂F₅N₃O₃S
• 分子量: 647.625
• InChiKey: TUNWLXYVCSQWKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  46
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  89.4
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  5-(3,5-difluorobenzenesulfonyl)-3-(trifluoroacetamido)-1-tritylindazole 在 甲醇 、 三乙胺 作用下， 反应 5.0h， 以3.46 g的产率得到3-amino-5-(3,5-difluorobenzenesulfonyl)-1-tritylindazole
  参考文献：
  名称：

  Development of Scaffold Synthesis for the Preparation of New Insulin-Like Growth Factor 1 Receptor Inhibitors

  摘要：

  The synthesis of new insulin-like growth factor 1 receptor (IGF-1R) inhibitors is reported. The described molecules have a new sulfonyl-indazole structure. We describe the process research and development for the scaffold synthetic procedure in order to provide the large amount of product required for lead optimization, candidate selection, and preclinical studies.

  DOI：

  10.1021/op8002536
• 作为产物：
  描述：

  5-(3,5-difluorobenzenesulfonyl)-3-(trifluoroacetamido)indazole 、 三苯基氯甲烷 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.08h， 生成 5-(3,5-difluorobenzenesulfonyl)-3-(trifluoroacetamido)-1-tritylindazole
  参考文献：
  名称：

  Development of Scaffold Synthesis for the Preparation of New Insulin-Like Growth Factor 1 Receptor Inhibitors

  摘要：

  The synthesis of new insulin-like growth factor 1 receptor (IGF-1R) inhibitors is reported. The described molecules have a new sulfonyl-indazole structure. We describe the process research and development for the scaffold synthetic procedure in order to provide the large amount of product required for lead optimization, candidate selection, and preclinical studies.

  DOI：

  10.1021/op8002536

文献信息

• INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Bandiera Tiziano

  公开号：US20100197665A1

  公开（公告）日：2010-08-05

  Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a dysregulated protein kinase activity, like cancer formula (I).

  本发明揭示了公式（I）的取代吲唑衍生物及其药学上可接受的盐，其定义在说明书中，以及其制备过程和包含它们的制药组合物；本发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症公式（I）中有用。
• US8114865B2
  申请人：——

  公开号：US8114865B2

  公开（公告）日：2012-02-14
• [EN] INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE L'INDAZOLE EN TANT QU'INHIBITEURS DES KINASES POUR LE TRAITEMENT DU CANCER
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2008074749A1

  公开（公告）日：2008-06-26

  [EN] Substituted indazole derivativesof formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a dysregulated protein kinase activity, like cancer. formula (I)
  [FR] La présente invention concerne des dérivés d'indazole substitués de formule (I) et leurs sels pharmaceutiquement acceptables, tels que définis dans le mémoire descriptif, leur procédé de préparation et des compositions pharmaceutiques qui les comprennent. Les composés selon l'invention ont une utilisation thérapeutique pour le traitement de maladies associée à une activité protéine-kinase déréglée telles que le cancer. Formule (I)
• Development of Scaffold Synthesis for the Preparation of New Insulin-Like Growth Factor 1 Receptor Inhibitors
  作者：Ilaria Candiani、Germano D’Arasmo、Franco Heidempergher、Attilio Tomasi

  DOI：10.1021/op8002536

  日期：2009.5.15

  The synthesis of new insulin-like growth factor 1 receptor (IGF-1R) inhibitors is reported. The described molecules have a new sulfonyl-indazole structure. We describe the process research and development for the scaffold synthetic procedure in order to provide the large amount of product required for lead optimization, candidate selection, and preclinical studies.